PHATHOM PHARMACEUTICALS INC (PHAT) Institutional Shareholders
PHATHOM PHARMACEUTICALS INC (PHAT) is currently reported in institutional portfolios tracked by InsiderSet based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026. The institutional investors covered on this page collectively reported approximately $778.42M in PHAT holdings during the latest filing period.
Frazier Life Sciences Management, L.P. is currently the largest disclosed institutional shareholder of PHAT tracked by InsiderSet, reporting ownership valued at approximately $135.26M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $93.25M, representing an estimated loss of -31.06% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 61% of the total disclosed PHAT value among the investors covered in this analysis. Major shareholders include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Blackrock, Inc., and several other long-term asset managers with concentrated positions in PHATHOM PHARMACEUTICALS INC (PHAT).
This page ranks the largest institutional PHAT shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
Institutional Holders
160
Total Reported Value
$778.42M
Largest Holder
Frazier Life Sciences Management, L.P.
Largest Position
$135.26M
Insider Transactions (90d)
2
Latest Filing Quarter
Q2 2026
New Institutional Positions
72
Funds Exiting Positions
0
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 2.95% | 12,466,489 | $135,261,406 | $93,249,338 | -$42,012,068 | -31.06% | |
| Medicxi Ventures Management (Jersey) Ltd | 45.65% | 7,464,572 | $80,990,606 | $55,834,999 | -$25,155,607 | -31.06% | |
| Blackrock, Inc. | 0.00% | 4,525,129 | $49,097,648 | $33,847,965 | -$15,249,683 | -31.06% | |
| Invesco Ltd. | 0.00% | 4,029,731 | $43,722,581 | $30,142,388 | -$13,580,193 | -31.06% | |
| Carlyle Group Inc. | 0.38% | 3,496,808 | $37,940,367 | $26,156,124 | -$11,784,243 | -31.06% | |
| Millennium Management Llc | 0.02% | 3,375,834 | $36,627,799 | $25,251,238 | -$11,376,561 | -31.06% | |
| Vanguard Capital Management Llc | 0.00% | 2,656,944 | $28,827,842 | $19,873,941 | -$8,953,901 | -31.06% | |
| Gw&K Investment Management, Llc | 0.18% | 2,166,838 | $23,510,000 | $16,207,948 | -$7,302,052 | -31.06% | |
| Nea Management Company, Llc | 1.34% | 1,960,169 | $21,267,834 | $14,662,064 | -$6,605,770 | -31.06% | |
| 683 Capital Management, Llc | 1.85% | 1,850,000 | $20,072,501 | $13,838,000 | -$6,234,501 | -31.06% | |
| Goldman Sachs Group Inc | 0.00% | 1,778,032 | $19,291,647 | $13,299,679 | -$5,991,968 | -31.06% | |
| Ensign Peak Advisors, Inc | 0.03% | 1,627,806 | $18,084,925 | $12,175,989 | -$5,908,936 | -32.67% | |
| State Street Corp | 0.00% | 1,586,323 | $17,211,605 | $11,865,696 | -$5,345,909 | -31.06% | |
| Catalys Pacific, Llc | 7.06% | 1,493,854 | $16,208,316 | $11,174,028 | -$5,034,288 | -31.06% | |
| Nomura Asset Management International Inc. | 0.02% | 1,462,738 | $15,871,000 | $10,941,280 | -$4,929,720 | -31.06% | |
| Geode Capital Management, Llc | 0.00% | 1,315,687 | $14,277,589 | $9,841,339 | -$4,436,250 | -31.07% | |
| Wasatch Advisors Lp | 0.09% | 1,307,247 | $14,183,630 | $9,778,208 | -$4,405,422 | -31.06% | |
| Catalio Capital Management, Lp | 2.05% | 698,996 | $11,596,344 | $5,228,490 | -$6,367,854 | -54.91% | |
| Propel Bio Management, Llc | 5.96% | 1,050,358 | $11,396,384 | $7,856,678 | -$3,539,706 | -31.06% | |
| Point72 Asset Management, L.P. | 0.02% | 1,022,193 | $11,090,794 | $7,646,004 | -$3,444,790 | -31.06% | |
| Vanguard Portfolio Management Llc | 0.00% | 796,631 | $8,643,446 | $5,958,800 | -$2,684,646 | -31.06% | |
| Summittx Capital, L.P. | 0.23% | 789,550 | $8,566,618 | $5,905,834 | -$2,660,784 | -31.06% | |
| Hsbc Holdings Plc | 0.00% | 709,695 | $7,701,936 | $5,308,519 | -$2,393,417 | -31.08% | |
| Marshall Wace, Llp | 0.01% | 666,090 | $7,227,078 | $4,982,353 | -$2,244,725 | -31.06% | |
| Ecor1 Capital, Llc | 0.34% | 625,000 | $6,781,250 | $4,675,000 | -$2,106,250 | -31.06% | |
| Perceptive Advisors Llc | 0.09% | 532,000 | $5,772,200 | $3,979,360 | -$1,792,840 | -31.06% | |
| Two Sigma Investments, Lp | 0.00% | 519,076 | $5,631,975 | $3,882,688 | -$1,749,287 | -31.06% | |
| Northern Trust Corp | 0.00% | 458,301 | $4,972,565 | $3,428,091 | -$1,544,474 | -31.06% | |
| Stepstone Group Lp | 0.21% | 422,085 | $4,579,622 | $3,157,196 | -$1,422,426 | -31.06% | |
| Charles Schwab Investment Management Inc | 0.00% | 419,094 | $4,547,170 | $3,134,823 | -$1,412,347 | -31.06% | |
| Woodline Partners Lp | 0.01% | 369,052 | $4,004,214 | $2,760,509 | -$1,243,705 | -31.06% | |
| Vanguard Fiduciary Trust Co | 0.00% | 354,573 | $3,847,117 | $2,652,206 | -$1,194,911 | -31.06% | |
| Hennion & Walsh Asset Management, Inc. | 0.10% | 327,278 | $3,550,966 | $2,448,039 | -$1,102,927 | -31.06% | |
| Ameriprise Financial Inc | 0.00% | 293,979 | $3,189,673 | $2,198,963 | -$990,710 | -31.06% | |
| Jpmorgan Chase & Co | 0.00% | 275,251 | $2,991,978 | $2,058,877 | -$933,101 | -31.19% | |
| Simplify Asset Management Inc. | 0.04% | 249,267 | $2,704,547 | $1,864,517 | -$840,030 | -31.06% | |
| Renaissance Technologies LLC | Jim Simons | 0.00% | 226,400 | $2,456,440 | $1,693,472 | -$762,968 | -31.06% |
| Jane Street Group, Llc | 0.00% | 212,706 | $2,307,860 | $1,591,041 | -$716,819 | -31.06% | |
| Ubs Group Ag | 0.00% | 204,573 | $2,219,618 | $1,530,206 | -$689,412 | -31.06% | |
| Newedge Advisors, Llc | 0.01% | 203,962 | $2,212,988 | $1,525,636 | -$687,352 | -31.06% | |
| Avidity Partners Management Lp | 0.35% | 200,000 | $2,170,000 | $1,496,000 | -$674,000 | -31.06% | |
| Morgan Stanley | 0.00% | 199,909 | $2,169,013 | $1,495,319 | -$673,694 | -31.06% | |
| Jump Financial, Llc | 0.02% | 191,866 | $2,081,746 | $1,435,158 | -$646,588 | -31.06% | |
| Opaleye Management Inc. | 0.18% | 185,589 | $2,013,641 | $1,388,206 | -$625,435 | -31.06% | |
| Citadel Advisors Llc | 0.00% | 184,901 | $2,006,176 | $1,383,059 | -$623,117 | -31.06% | |
| Trexquant Investment Lp | 0.01% | 173,884 | $1,886,641 | $1,300,652 | -$585,989 | -31.06% | |
| Jones Hill Capital Lp | 0.37% | 161,486 | $1,752,123 | $1,207,915 | -$544,208 | -31.06% | |
| Bank Of New York Mellon Corp | 0.00% | 152,313 | $1,652,595 | $1,139,301 | -$513,294 | -31.06% | |
| Wells Fargo & Company/Mn | 0.00% | 152,002 | $1,649,221 | $1,136,975 | -$512,246 | -31.06% | |
| Bank Of America Corp | 0.00% | 151,015 | $1,638,513 | $1,129,592 | -$508,921 | -31.06% |
Frequently asked questions about PHAT
Who owns the most PHAT stock?
The largest holders of PHAT are typically major institutional investors such as asset managers and hedge funds reporting on Form 13F. The table above ranks tracked superinvestors by reported position size using the latest available filings for PHATHOM PHARMACEUTICALS INC (PHAT).
Is PHAT widely held by superinvestors?
Many widely followed stocks like PHAT appear across numerous superinvestor portfolios because of liquidity, index inclusion, and fundamentals. The holder count and table above show how broadly PHAT is represented among the institutional managers we track.
What do “Current Estimated Value”, “Gain/loss Since Filing”, and “Estimated Portfolio Performance” mean?
Current Estimated Value is reported share quantity from the latest 13F times our most recent split-adjusted U.S. session close. Gain/loss Since Filing is that estimate minus the reported 13F dollar value; Estimated Portfolio Performance is that difference as a percent of the reported value. Green means the estimate is above the filing value; red means below (not purchase cost). If many filers share the same implied filing price per share, the performance % may match across rows. These are not official fund marks or live quotes.